For a 23‑year‑old with severe eosinophilic, steroid‑dependent asthma who has a rebound eosinophil count of ~700 cells/µL after a prednisone burst and normal IgE, how do the asthma biologics compare and which is the most appropriate choice?

Mepolizumab or Benralizumab Are the Optimal First-Line Biologics for This Patient

For a 23-year-old with severe eosinophilic, steroid-dependent asthma (eosinophil count 700 cells/µL, normal IgE), mepolizumab, benralizumab, or reslizumab (all anti-IL5/IL5R agents) are the preferred biologic choices, with mepolizumab having the most evidence in this specific clinical scenario. 1

Biologic Selection Based on Phenotype

Your patient has eosinophilic asthma (elevated blood eosinophils with normal IgE), which is a type 2 inflammatory endotype. 1 The 2025 Rhinology guidelines explicitly recommend for eosinophilic asthma: mepolizumab, reslizumab, or benralizumab (all anti-IL5/IL5R pathway agents). 1

Why Anti-IL5/IL5R Agents Are Optimal Here:

• Direct eosinophil targeting: These agents specifically address the pathophysiology driving this patient's disease—elevated eosinophils that rebound after steroid withdrawal. 1
• Steroid-sparing efficacy: In steroid-dependent eosinophilic asthma, anti-IL5 therapy has demonstrated significant reduction in oral corticosteroid requirements while maintaining asthma control. 2, 3
• Blood eosinophil ≥150/µL predicts response: This patient's count of 700 cells/µL far exceeds the threshold for identifying responders to anti-IL5 therapy. 4

Comparison of Specific Biologics

Mepolizumab (Anti-IL5)

• Dosing: 100 mg subcutaneous every 4 weeks (300 mg for certain indications). 2
• Evidence: Most extensively studied in steroid-dependent eosinophilic asthma, with proven efficacy in reducing exacerbations and oral steroid burden. 5, 6, 2
• Special consideration: Specifically recommended for "highly eosinophilic asthma" in the 2025 guidelines. 1
• Real-world data: 32% of EGPA patients (similar steroid-dependent eosinophilic phenotype) achieved ≤4 mg prednisone daily at 12 months; median dose reduced from 10 mg to 5 mg. 2

Benralizumab (Anti-IL5 Receptor)

• Dosing: 30 mg subcutaneous every 4 weeks for first 3 doses, then every 8 weeks. 2
• Mechanism advantage: Directly depletes eosinophils via antibody-dependent cell-mediated cytotoxicity, potentially more complete eosinophil reduction. 7, 8
• Convenience: Less frequent dosing (every 8 weeks after loading) may improve adherence. 2
• Equivalent efficacy: Real-world data shows similar steroid-sparing effects to mepolizumab in eosinophilic asthma. 2

Reslizumab (Anti-IL5)

• Dosing: 3 mg/kg IV every 4 weeks. 1
• Limitation: Requires IV infusion rather than subcutaneous self-administration, less convenient. 1
• Evidence: Effective for eosinophilic asthma but less practical for outpatient management. 1

Why NOT Other Biologics:

Omalizumab (Anti-IgE):

• Indicated for allergic asthma with elevated IgE. 1
• This patient has normal IgE, making omalizumab inappropriate. 1
• Only preferred in pregnancy planning scenarios. 1

Dupilumab (Anti-IL4Rα):

• Broader type 2 inflammation targeting (IL-4 and IL-13 pathways). 1
• Recommended for "type 2 asthma" generally or when nasal polyps coexist. 1
• Less specific for pure eosinophilic phenotype compared to anti-IL5 agents. 1
• Consider as second-line if anti-IL5 therapy fails. 1

Tezepelumab (Anti-TSLP):

• Indicated for both type 2 and non-type 2 asthma. 1
• Broader mechanism but less evidence in steroid-dependent eosinophilic asthma specifically. 1
• Reserve for patients who fail type 2-specific therapies or have mixed/unclear phenotype. 1

Practical Implementation

Initial Steps Before Biologic Initiation:

• Confirm diagnosis: Ensure variable airflow limitation documented, exclude mimics. 1
• Optimize inhaled therapy: Maximize ICS-LABA-LAMA triple therapy before biologics. 1
• Address comorbidities: Evaluate for chronic rhinosinusitis, GERD, anxiety/depression that may confound control. 1
• Verify adherence: Poor inhaler technique or non-adherence must be corrected first. 1

Monitoring Response:

• Assess at 8-12 weeks: Evaluate symptom improvement (≥50% reduction), ≥20% reduction in total IgE, and imaging improvement. 9
• Eosinophil monitoring: Expect significant reduction (median 365→55 cells/µL at 6 months with anti-IL5 therapy). 2
• Steroid tapering: Begin gradual prednisone reduction once response confirmed, aiming for ≤7.5 mg/day or discontinuation. 4
• Exacerbation tracking: Should see reduction from baseline exacerbation frequency. 2

Common Pitfalls to Avoid

• Don't choose omalizumab despite it being "safest in pregnancy"—this patient has normal IgE, making it ineffective. 1, 5
• Don't delay biologic initiation in truly steroid-dependent patients—prolonged high-dose steroids cause significant morbidity (osteoporosis, HPA suppression, infection risk). 4
• Don't stop ICS-LABA even after successful biologic therapy and steroid discontinuation—maintenance inhaled therapy must continue. 4
• Don't expect immediate response—biologics require weeks to months for full effect; plan steroid taper accordingly. 1
• Don't ignore rebound eosinophilia as a marker of inadequate control—this patient's 700 cells/µL post-prednisone indicates active type 2 inflammation requiring targeted therapy. 4, 10

If First Biologic Fails:

• Switch within class (e.g., mepolizumab to benralizumab) or switch mechanism (to dupilumab or tezepelumab). 1
• Re-evaluate phenotype: Consider induced sputum eosinophils if available to confirm eosinophilic endotype. 4
• Consider azithromycin: 250-500 mg three times weekly may reduce exacerbations as adjunct. 4